Results 1 to 10 of about 775,328 (297)

Epigenetic insights into minimal residual disease detection in cancer [PDF]

Genes and Diseases
Lingao Ju, Gang Wang, Zilin Xu, Wan Xiang, Hongwei Peng, Mengxue Yu, Shenjuan Li, Yi Zhang, Kaiyu Qian, Yu Xiao   +9 more
doaj   +3 more sources

Minimal Residual Disease, Metastasis and Immunity [PDF]

Biomolecules, 2021
Progression from localized to metastatic disease requires cancer cells spreading to distant organs through the bloodstream. Only a small proportion of these circulating tumor cells (CTCs) survives dissemination due to anoikis, shear forces and ...
Jordi Badia-Ramentol, Jenniffer Linares, Andrea Gómez-Llonin, Alexandre Calon   +3 more
doaj   +3 more sources

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications

Frontiers in Oncology, 2022
Multiple Myeloma (MM), the second most common hematologic malignancy, has been the target of many therapeutic advances over the past two decades. The introduction of novel agents, such as proteasome inhibitors, immunomodulatory drugs, and monoclonal ...
Charalampos Charalampous, Taxiarchis Kourelis   +1 more
doaj   +2 more sources

Assessment of Minimal Residual Disease in Standard-Risk AML [PDF]

New England Journal of Medicine, 2016
BACKGROUND: Despite the molecular heterogeneity of standard-risk acute myeloid leukemia (AML), treatment decisions are based on a limited number of molecular genetic markers and morphology-based assessment of remission.
Akiki, S, Bhudia, N, Burnett, AK, Farah, H, Freeman, SD, Gale, RE, Gilkes, A, Grech, A, Griffiths, M, Grimwade, D, Hills, RK, Ivey, A, Jovanovic, JV, Linch, DC, Mason, J, McCaughan, F, Patel, Y, Russell, N, Simpson, MA, Solomon, E, Vyas, P, Wall, K   +21 more
core   +2 more sources

Role of minimal residual disease assessment in multiple myeloma

Haematologica
Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells. MM is a heterogeneous disease, featured by various molecular subtypes with different outcomes. With the advent of very efficient therapies including
Raphael Szalat, Kenneth Anderson, Nikhil Munshi   +2 more
doaj   +2 more sources

Evaluation of Minimal Residual Disease in Patients with Neuroblastoma. [PDF]

Mol Diagn Ther
Yamamoto N, Ishizawa K, Umemoto M, Nishimura A, Fujikawa T, Inoue S, Nakatani N, Tamura A, Nino N, Uemura S, Hasegawa D, Kosaka Y, Nishimura N.   +12 more
europepmc   +3 more sources

MINIMAL RESIDUAL DISEASE IN PERIPHERAL BLOOD ASSESSED BY MASS SPECTROMETRY

HemaSphere, 2022
Noemi Puig
doaj   +2 more sources

Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA

Journal for ImmunoTherapy of Cancer, 2023
Liquid biopsies using cell-free circulating tumor DNA (ctDNA) are being used frequently in both research and clinical settings. ctDNA can be used to identify actionable mutations to personalize systemic therapy, detect post-treatment minimal residual ...
N. Semenkovich, J. Szymanski, N. Earland, Pradeep S. Chauhan, B. Pellini, A. Chaudhuri   +5 more
semanticscholar   +1 more source

Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review

Frontiers in Genetics, 2023
Minimal residual disease (MRD) refers to a very small number of residual tumor cells in the body during or after treatment, representing the persistence of the tumor and the possibility of clinical progress.
Lemei Zhu, Ran Xu, Leilei Yang, W. Shi, Yuan Zhang, Juan Liu, Xi Li, Jun Zhou, Pingping Bing   +8 more
semanticscholar   +1 more source

Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer

Clinical Cancer Research, 2021
Purpose: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery can identify patients with minimal residual disease (MRD) who will ultimately recur.
A. Parikh, Emily E. Van Seventer, G. Siravegna, A. Hartwig, A. Jaimovich, Yupeng He, K. Kanter, M. Fish, Kathryn Fosbenner, B. Miao, S. Phillips, John H Carmichael, Nihaarika Sharma, Joy Jarnagin, I. Baiev, Yojan S. Shah, Isobel J. Fetter, Heather A. Shahzade, Jill N. Allen, L. Blaszkowsky, Jeffrey W. Clark, J. Dubois, J. Franses, B. Giantonio, L. Goyal, S. Klempner, R. Nipp, E. Roeland, D. Ryan, C. Weekes, J. Wo, T. Hong, L. Bordeianou, C. Ferrone, M. Qadan, H. Kunitake, D. Berger, R. Ricciardi, J. Cusack, V. Raymond, Amirali Talasaz, G. Boland, R. Corcoran   +42 more
semanticscholar   +1 more source